Related Experiment Videos
[Lethal arrhythmias--etiological view and therapeutic approach]
Takeshi Ueyama1, Kohshiro Moritani, Akihiko Shimizu
1Division of Cardiology, Yamaguchi Prefectural Central Hospital.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|July 26, 2002
Summary
Life-threatening arrhythmias, a cause of sudden cardiac death, are treated with drugs, pacemakers, and ablation. An upstream approach to arrhythmia prevention is increasingly recognized.
Area of Science:
- Cardiology
- Electrophysiology
- Genetics
Context:
- Life-threatening arrhythmias, including bradyarrhythmias and tachyarrhythmias, are a major cause of sudden cardiac death.
- These arrhythmias often stem from structural (e.g., ischemic fibrosis) or functional (e.g., heart failure, autonomic dysfunction) myocardial abnormalities.
- Primary electrical diseases, arising from genetic abnormalities, can also precipitate lethal arrhythmias.
Purpose:
- To review the current understanding and treatment strategies for life-threatening arrhythmias.
- To highlight the role of pharmacologic and non-pharmacologic therapies.
- To emphasize the emerging importance of preventive, upstream approaches to arrhythmia management.
Summary:
- Lethal arrhythmias result from myocardial structural/functional issues or primary genetic defects.
- Treatment options include pharmacologic agents (e.g., K channel blockers for tachyarrhythmias), non-pharmacologic therapies (pacemakers for bradyarrhythmias), and radiofrequency catheter ablation.
- Implantable cardioverter-defibrillators (ICDs) are crucial for managing high-risk patients.
Impact:
- Current meta-analyses support K channel blockers for lethal tachyarrhythmias.
- Pacemaker therapy is a standard non-pharmacologic treatment for bradyarrhythmias.
- Preventive strategies, such as upstream approaches to arrhythmia, are gaining recognition for reducing the incidence of sudden cardiac death.